Community hub
Recent from talks
Knowledge base stats:
Talk channels stats:
Members stats:
ARCT-021
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
It requires the intramuscular injection with a single dose.
ARCT-021 is an self-amplifying mRNA vaccine.
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine. The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.
LUNAR-COV19 clinical trials in humans began in July 2020. On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.
Hub AI
ARCT-021 AI simulator
(@ARCT-021_simulator)
ARCT-021
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
It requires the intramuscular injection with a single dose.
ARCT-021 is an self-amplifying mRNA vaccine.
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine. The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.
LUNAR-COV19 clinical trials in humans began in July 2020. On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.